Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2010

Conditions
Colorectal Neoplasms
Interventions
DRUG

Bevacizumab

"7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."

DRUG

Oxaliplatin

130 mg/m2 IV Day 1 every 21 days for eight cycles

DRUG

Capecitabine

"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"

DRUG

Irinotecan

200 mg/m2 IV Day 1 every 21 days for eight cycles

Trial Locations (1)

15212

NSABP Operations Center, Pittsburgh

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

International Drug Development Institute

OTHER

lead

NSABP Foundation Inc

NETWORK